Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Journal of Colorado.
Press releases published on August 11, 2025
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today …
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025
WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results …
Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approval Capricor seeks to resubmit its BLA based on its existing dataset, with HOPE-3 data (expected in Q4 2025) potentially serving as supportive and confirmatory …
Life360 Names COO Lauren Antonoff as Chief Executive Officer
Co-Founder Chris Hulls will serve as Executive Chairman of the Board Planned leadership succession signals continued investment in product innovation and growth SAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Life360 (Nasdaq: LIF), the category-defining …
Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates
Presented positive 6-month clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with stable C- …
Synchronoss Technologies Reports Second Quarter 2025 Results
Second Quarter Revenue of $42.5 Million, Including 92.6% Recurring Revenue Received CARES Act Tax Refund in Full, Amounting to $33.9 Million Reaffirms All Full Year Guidance Metrics BRIDGEWATER, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Synchronoss …
Assertio Reports Second Quarter 2025 Financial Results
Second Quarter Total Net Product Sales of $28.8 Million, Cash and Investments Increase to $98.2 Million Narrows Guidance on Continued Progress Implementing Long-Term Business Strategy LAKE FOREST, Ill., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, …
BioVie Inc. Announces Closing of $12 Million Public Offering
CARSON CITY, Nev., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and …
Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 …
TELA Bio Reports Second Quarter 2025 Financial Results
MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended …
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 million Transaction …
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launch DNL126 accelerated approval path for Sanfilippo syndrome Type A aligned with FDA; Phase …
Mercury Systems Reports Fourth Quarter and Fiscal 2025 Results
Record Q4 FY25 Bookings of $341.5 million; book-to-bill of 1.25 Record backlog of $1.40 billion; up 6% year-over-year Q4 FY25 Revenue of $273.1 million; GAAP net income of $16.4 million; and adjusted EBITDA of $51.3 million Q4 FY25 Operating Cash Flow of $ …
Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026 Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDA Company accelerates Anaphylm global expansion strategy to Canada and the EU Company to host …
Rapid7 to Participate in Upcoming Investor Conferences
BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a leader in threat detection and exposure management, today announced that the company will be attending the following conferences: The Canaccord Genuity 45th Annual Growth Conference in …
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to Support Operating Plans at Least into 2029 …
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
Net income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128 million Ping Zhang, Executive Chairman, appointed interim CEO as Dr. Han Ying transitions to …
Harrow Announces Second-Quarter 2025 Financial Results
Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year period GAAP net income of $5.0 million Adjusted EBITDA of $17.0 million Cash and cash equivalents of $53.0 …
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Daix (France), New York City (New York, United States), August 11, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment …
Inventiva Participera à la « Canaccord Genuity 45th Annual Growth Conference »
Daix (France), New York City (New York, Etats-Unis), le 11 aout 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la …